CareMed Has Been Selected as a National Specialty Pharmacy Provider for MYQORZO™ (aficamten) [Yahoo! Finance]
Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Cytokinetics (NASDAQ:CYTK) was given a new $90.00 price target on by analysts at Morgan Stanley.
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf